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Purpose: The aim of this study was to quantify the ability to identify odors in normal tension glaucoma (NTG) patients
and healthy subjects with and without a primary vascular dysregulation (PVD).
Methods: Both self-assessment of smell perception and evaluation of odor identification by means of the 12-item odor
identification test (“Sniffin’ Sticks”) were performed in the following groups of subjects: 1) 18 NTG patients with PVD
(G+), 2) 18 NTG patients without PVD (G-), 3) 18 healthy subjects with PVD (H+) and 4) 18 healthy subjects without
PVD (H-). The subjects self-assessment of smell perception was evaluated before the Sniffin’ Sticks test by asking them
to judge their ability to identify odors as either “average,” “better than average,” or “worse than average.”
Results: Subjects with a PVD (G+ and H+) can identify odors significantly better than those without a PVD (G- and H-;
in a score scale of 1–12 the score point difference=2.64, 95% CI=1.88–3.40, p<0.001). No significant differences in odor
identification was found between NTG (groups G+ and G-) and healthy subjects (groups H+ and H-; score point
difference=-0.14, 95% CI=-0.9–0.62, p=0.72).
Conclusions: Subjects with a PVD can identify odors significantly better than those without a PVD.
Smell perception can have a significant impact on our
lives [1]. When the sense of smell is lost, it is not just that we
cannot differentiate between different smells or enjoy what
we eat or drink but we are also not as alert to dangers [2].
Similarly, an enhanced perception of the sense of smell may
be just as disturbing [3,4]. The increased sense of smell to
different odors can be overwhelming enough to cause nausea,
sneezing, headaches or eye pain [5,6].
Disturbances in smell perception are not infrequent [7,
8], particularly in patients with neurodegenerative diseases
such  as  Parkinson  disease  [9],  for  instance.  Olfactory
dysfunction among subjects below 65 years of age is more
frequent  than  previously  reported  [10].  Patients  often
complain to their physicians about both disturbances of hypo-
and hyperosmia [11]. We have had similar experiences with
normal  tension  glaucoma  patients  (NTG).  Our  clinical
observations implied that those patients with the better sense
of smell had a primary vascular dysregulation (PVD).
PVD is an inborn predisposition to respond different to
various stimuli [12,13]. PVD individuals tend to more often
have: cold hands or feet even in the summer [14], a reduced
feeling of thirst [15], a low blood pressure especially when
they are young [16], a longer sleep onset time [17], migraines
in comparison to non-PVD subjects [18], and an altered drug
sensitivity due to differential expression of ABC transporter
proteins [19].
Other leading signs of PVD include increased level of
Endothelin-1  [20],  blood-pressure  dependent  Endothelin-
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sensitivity  [21],  and  an  increased  prevalence  of  silent
myocardial ischemia [22]. PVD subjects also have a higher
risk for certain diseases. This includes the risk of anterior
ischemic  optic  neuropathy  (AION)  [23],  vein  occlusions
[24],  central  serous  chorioretinopathy  [25,26],  as  well  as
glaucoma [27,28].
In  terms  of  circulation,  PVD  subjects  respond  more
strongly with vasoconstriction to mechanical stress (e.g., whip
lash trauma), psychological stress, or coldness [12]. Analysis
of  their  retinal  circulation  has  shown  that  these  subjects
respond  less  to  flickering  light  (neurovascular  coupling)
[29], they have increased spatial irregularities [30], fast pulse
waves indicating higher stiffness of vessels [31], and altered
blood-brain  and  blood-retinal  barrier  including  increased
prevalence of splinter hemorrhages [32]. In PVD subjects
relationships between finger circulation and visual field [14],
finger circulation and ophthalmic artery blood flow [33], as
well as between corneal temperature and finger temperature
have been described [34]. The aim of the present study was to
examine  whether  NTG  or  PVD  subjects  have  a  different
ability to smell. We therefore quantified the ability to identify
odors in four groups of subjects, namely, NTG patients with
and without PVD as well as healthy subjects with and without
PVD.
METHODS
Participants: Patients with normal tension glaucoma (NTG)
were recruited from the University Eye Clinic Basel (Basel,
Switzerland)  between  January  2009  and  December  2009.
Healthy volunteers, age and sex matched to NTG patients,
were recruited after a notification in the University Clinic
informed potential volunteers of the opportunity to participate
in a scientific research project. Ethical approval was obtained
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506from the local medical ethics committee, and written informed
consent was received from all subjects before entry into the
study. The study was designed and conducted in accordance
with the tenets of Declaration of Helsinki.
Patients with NTG had to meet the following inclusion
criteria: (1) untreated intraocular pressure (IOP) less than
21 mmHg on multiple measurements, (2) progressive changes
in either visual fields or optic nerve cupping, and (3) the
absence of other known causes of optic neuropathy than glau
coma.
PVD was defined as being present (PVD+) if the subjects
answered three of the following seven questions with “Yes,”
and it was defined as being absent (PVD-) if the subjects
answered less than three questions with “Yes”: 1) Do you
suffer from cold hands or feet even in summer [14], 2) Do you
have  trouble  falling  asleep,  especially  when  you  are  cold
[17], 3) Are you seldom thirsty and do you have to remind
yourself to drink enough [15], 4) Do you suffer from tinnitus
[13], 5) Do you suffer from migraine attacks [18], 6) Do you
have  a  rather  low  blood  pressure  [16],  7)  Do  you  react
sensitively to certain medications [19]. Demographic data of
the different groups of participants are given in Table 1.
Self-assessment:  All  participants  rated  their  perception  of
smell as either “average,” “better than average” or “worse than
average”  before  the  Sniffin’  Sticks  test  (Burghart  GmbH,
Wedel, Germany) was performed.
Sniffin’ Sticks test: The 12-item “Sniffin’ Sticks” test battery
is a validated test for the evaluation of identification of odors
[35].  This  olfactory  test  kit  consisted  of  pen-like  odor-
dispensing devices (“Sniffin’ Sticks”). Twelve odors were
presented in a randomized sequence. Subjects were allowed
to sample the odors one time before identifying them from a
list of four descriptors. The test score which varied from 0
(worst) to 12 (best) was the sum of the correctly identified
odors. The experimenter (DH) was not informed as to which
group the test person belonged to. She (DH) presented odor
pens to both nostrils of participants separated by an interval
of 20–30 s to prevent olfactory desensitization.
Statistical analysis: To predict score points from NTG status
and PVD status, a linear regression model was performed.
Independent variables were NTG status and PVD status as
well as an interaction between both variables. Results are
presented as differences of means between PVD+ and PVD-
groups  as  well  as  differences  between  NTG  and  healthy
groups. Differences were estimated with corresponding 95%
confidence intervals (CI). To predict score points from self-
assessment a linear model was also used. A p value <0.05 is
considered as significant. All analyses were done using the
statistical  package  R  version  2.4.0  (SPSS  2006,  Basel,
Switzerland).
RESULTS
Results of the subject’s self-assessment of smell perception
before Sniffin’ Sticks test are given in Table 2. There was no
significant  interaction  between  NTG  and  PVD  (p=0.94),
indicating  the  same  score  difference  in  each  PVD  group.
Consequently, the interaction was deleted from the regression
model. Subjects with a PVD (G+ and H+) could identify odors
significantly better than those without a PVD (G- and H-;
p<0.001;  Figure  1).  No  significant  differences  in  odor
identification  was  found  between  NTG  (G+  and  G-)  and
healthy  subjects  (H+  and  H-;  p=0.72).  No  change  was
observed after correcting for age. Subjects with a better self
assessment before Sniffin’ Sticks test had significantly higher
score points (p<0.001; Table 3).
DISCUSSION
In the present study we found that both NTG patients and
healthy individuals having a PVD are able to identify various
odors  better  than  those  without  a  PVD.  As  previously
mentioned, individuals with a PVD on average tend to respond
different to different stimuli [13]. When drugs, for example,
are prescribed to PVD subjects they often respond stronger,
at times even violently to certain class of drugs. Similarly, they
respond less than the average person to a few other classes of
drugs. This might be due to a different expression of the ABC
transport proteins in these PVD individuals [19].
Proteins also play a role in smell perception. Odorant
binding proteins, which are found in the human olfactory
mucus  [36],  bind  to  different  odorants.  They  are  small
TABLE 1. DEMOGRAPHIC DATA OF THE DIFFERENT GROUPS OF PARTICIPANTS.
      Gender
      Male Female
Group Mean age N N % N %
G+ 61.6 18 9 50 9 50
G- 58.5 18 3 17 15 83
H+ 56.3 18 10 56 8 44
H- 53.4 18 9 50 9 50
Demographic data of the different groups of participants showing number (N) of participants in each group, mean age and gender
distribution. G+=NTG patients with PVD; G-=NTG patients without PVD; H+=Healthy subjects with PVD; H-=Healthy subjects
without PVD; PVD=Primary vascular dysregulation.
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superfamily [37-39]. These proteins, secreted by the olfactory
epithelium  in  the  nasal  mucus  of  vertebrates,  are  carrier
proteins [40]. It is thought that these proteins act as lipophilic
ligands which transfer odorants across the mucous layer to the
receptors  and  thereby  increase  the  concentration  of  the
odorants in the layer, relative to air [41-43]. A differential
expression of these odorant binding proteins, similar to the
differential expression found in ABC transport proteins, may
be one explanation for the altered smell perception in PVD
subjects.
Olfactory genes form the largest multi-gene family in
humans  [44,45].  These  genes  encode  olfactory  receptors,
which interact with odorant molecules in the nose to initiate
a  neuronal  response  that  triggers  the  perception  of  smell.
These olfactory receptors are G protein-coupled receptors;
upon odorant binding, these receptors couple to G proteins,
resulting  in  an  increase  in  intracellular  cAMP  levels  and
subsequent  receptor  signaling  [46].  The  altered  smell
TABLE 2. SELF-ASSESSMENT OF SMELL PERCEPTION BEFORE SNIFFIN’ STICKS TEST. SCORES ARE GIVEN IN %.
Group N Average %             Better than average % Worse than average %
G+ 18 39 50 11
G- 18 56 0 44
H
+ 18 33 61 6
H- 18 11 11 78
This table depicts the subject’s self-assessment of their smell perception prior to the Sniffin’ Sticks test. The participants were
asked  to judge their ability to smell as either “average”, “better than average” or “worse than average". In the table, G+=NTG
patients with PVD; G-=NTG patients without PVD; H+=Healthy subjects with PVD; H-=Healthy subjects without PVD;
PVD=Primary vascular dysregulation.
Figure 1. Sniffin’ Sticks score results in
healthy and  normal tension  glaucoma
(NTG) subjects. Healthy subjects with a
PVD as well as glaucoma patients with
a PVD could identify odors better than
those without a PVD.
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an altered expression of these receptors.
As  with  the  TAS2R50  bitter  receptor  gene,  a  single
nucleotide polymorphism in the OR13G1 (olfactory receptor,
family 13, subfamily G, member 1) gene has been linked with
an increased risk of myocardial infarction [47]. This olfactory
receptor gene may play an indirect role in increasing the risk
of myocard infarction by affecting food preferences that are
determined by the sense of smell. Similarly, we could argue
an  olfactory  receptor  gene  may  play  an  indirect  role  in
increasing the risk for a PVD syndrome.
In conclusion, subjects with a PVD can identify odors
significantly better than those without a PVD. We do not know
the  cause  of  this  different  smell  perception  and  can  only
speculate on it. Further research on the role of odorant-binding
proteins and the genetics of olfactory receptors is warranted.
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